Business Context and Reporting Period
This Form 8-K was filed by Blue Water Biotech, Inc. (Nasdaq: BWV), although the request metadata identifies Onconetix, Inc.; the filing text does not reference Onconetix. The report covers events beginning October 4, 2023, and was signed October 10, 2023. The company is an emerging growth company.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
- Neil Campbell received a $75,000 signing bonus and an annual base salary of $475,000.
- Campbell is eligible for a discretionary annual bonus of up to 50% of base salary.
- Bruce Harmon received an annual base salary of $325,000 and is eligible for a discretionary annual bonus of up to 30% of base salary.
- Campbell received an option to purchase 3% of the company’s outstanding common stock, and Harmon received an option to purchase 1%, each with an exercise price of $0.4305 per share and quarterly vesting over three years.
- Former CFO Jon Garfield is entitled to two months of severance under a separation agreement.
Material Changes Versus the Prior Comparable Period
- Effective October 4, 2023, Dr. Neil Campbell was appointed President, Chief Executive Officer, and a Class III director, with his term extending until the 2024 annual meeting.
- Jon Garfield resigned as Chief Financial Officer and was replaced by Bruce Harmon, effective immediately.
- James Sapirstein became non-executive Chairman rather than assuming the previously contemplated Interim Executive Chairman role. He remained Lead Independent Director through October 31, 2023.
- Sapirstein’s Lead Independent Director compensation was increased from $25,000 to $40,000 per month for August through October 2023.
- The company adopted a standard indemnification agreement for its officers and directors.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing provides no financial guidance or forecast. The appointments represent a significant change in senior leadership and include substantial fixed compensation, discretionary bonus opportunities, equity awards, and severance obligations. The employment agreements include non-compete and non-solicitation covenants. The filing states that Campbell and Harmon had no family relationships with company directors or officers and no reportable related-party interests under Item 404(a).
Investor Verification Items
- Confirm the registrant’s identity: the filing names Blue Water Biotech, Inc., not Onconetix, Inc.
- Review the full Campbell and Harmon employment agreements, including termination provisions, bonus discretion, and equity award terms.
- Verify the dilution impact of options representing 4% of outstanding common stock as of October 4, 2023.
- Review Garfield’s separation agreement and the company’s indemnification agreement.
- Assess the company’s subsequent filings for financial condition, liquidity, operating performance, and the effect of the leadership transition.